Two-Year Safety and Effectiveness of Peficitinib in Moderate-To-Severe Rheumatoid Arthritis: A Phase IIb, Open-Label Extension Study

by Mark C. Genovese, Maria W. Greenwald, Sergio R. Gutierrez-Ureña, Mario H. Cardiel, Jeffrey E. Poiley, Anna Zubrzycka-Sienkiewicz, Christine E. Codding, Annie Wang, Weizhong He, Rebecca Amos, Raul Vinueza, Xuegong Wang, Jay P. Garg, Alan J. Kivitz
Published 2019-08-01